TerminatedPHASE1, PHASE2NCT02393248
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Studying Myeloproliferative neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Luis Féliz, MDIncyte Corporation
- Intervention
- Pemigatinib(drug)
- Enrollment
- 201 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2021
Study locations (20)
- University of Alabama At Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
- Cedars-Sinai Medical Center, West Hollywood, California, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Hematology Oncology Associates of the Tr, Port Saint Lucie, Florida, United States
- Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
- University of Michigan Health System, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
- Northwell Health - Monter Cancer Center, New Hyde Park, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Ohio State University - Wexner Medical Center, Columbus, Ohio, United States
- Signal Point Clinical Research Center, Middletown, Ohio, United States
- Greenville Health System Cancer Institute, Greenville, South Carolina, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02393248 on ClinicalTrials.govOther trials for Myeloproliferative neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07441694Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation
- RECRUITINGPHASE2NCT07148947Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- RECRUITINGPHASE2NCT07228624Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesFred Hutchinson Cancer Center
- RECRUITINGNANCT07119970Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)University Hospital, Bordeaux
- RECRUITINGPHASE2NCT06661915A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)National Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentia
- RECRUITINGNCT07165535Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology NetworkUniversity of Milano Bicocca
- RECRUITINGNANCT05745285Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareUniversity of Miami